Orders for Merck & Co's oral antiviral for COVID-19 helped to swell the ... but even without the drug sales would have risen 19% thanks to a strong performance from cancer immunotherapy Keytruda ...

Investors have taken to punishing pharma companies that appear unable to gauge demand for their top products. Consider Pfizer. The company’s inability to accurately project demand for its Covid-19 ...

Investors are undervaluing promising drug candidates on the horizon for the two pharma giants, write Yale SOM’s Jeffrey ...

Eliquis, a blood thinner marketed in partnership with Bristol Myers Squibb, is Pfizer's largest revenue stream at the moment.

Pfizer and Merck, ostensibly beleaguered drugmakers, have seen their shares battered despite reporting strong earnings.

Collectively, the top eight blockbuster drugs of 2024 generated over $116 billion in sales last year. Looking closer at these ...